Topics
in vogue
AI
Amazon
Image Credits:Nasir Kachroo/NurPhoto / Getty Images
Apps
Biotech & Health
clime
Image Credits:Nasir Kachroo/NurPhoto / Getty Images
Cloud Computing
Commerce
Crypto
endeavor
EVs
Fintech
fund raise
Gadgets
Gaming
Government & Policy
ironware
layoff
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
security measures
Social
Space
Startups
TikTok
transportation system
Venture
More from TechCrunch
Events
Startup Battlefield
StrictlyVC
Podcasts
video
Partner Content
TechCrunch Brand Studio
Crunchboard
get through Us
Cancer , one of the most life - threatening diseases , is projected toaffect over 35 million peopleworldwide in 2050 — 77 % more than the estimated 20 million cases in 2022 , according to the World Health Organization . Cancer the Crab survivors globally reach out 53.5 million , and the recurrence rate of the disease motley between 15 % and 100 % , depending on the cancer type and stage and each patient role ’s situation . Despite this , the world currently lacks effective resolution for diagnosing to help curtail return .
EnterOneCell Diagnostics , a genomics - based startup in preciseness oncology that aims to help malignant neoplastic disease survivors limit return instances through its proprietary cell biopsy technology .
The inauguration , which has serve virtually 10,000 patient role in India and is looking to replicate its early success in India in the U.S. , has modernise its in - house blood - based biopsy examination that helps detect cancer ’s return through pass on tumor cell . This is unlike the widely used Crab detection methods , let in PET scans , CT CAT scan , magnetic resonance imaging , and tissue - ground diagnosis .
OneCell has secured an informatics to capture and isolate the circulating neoplasm cell from a 10 ml stemma haul . A phlebotomist visits the patient role ’s household to gather the blood line drawn in two tubes : one for detecting circulating tumour DNA ( ctDNA ) and the other for notice circulating tumor cell . These tubes are then sent to a nearby OnCell lab , where the blood sample goes through an depth psychology using a combining of scientific method acting and AI to predict recurrence , which it calls True - Single - Cell - Multi - omics . The startup combines the broadcast tumor mobile phone DNA with its RNA and cellular phone Earth’s surface protein examination .
This help provide better diagnosis , with at least 100 times more information than the current liquified biopsy examination , which largely revolves around cubicle - complimentary deoxyribonucleic acid and ctDNA , said cobalt - father and CEO Mohan Uttarwar .
The startup has also develop an app called iCare , which works as a precision oncology console to help oncologists read test report using AI and machine learning . “ It ’s the invention at the convergence of very deep science , the cell science , and datum skill , and that is a perfect storm , ” Uttarwar told TechCrunch .
While oncologist have the medical noesis , they are not well - aim in precision oncology , he said . OneCell ’s iCare offers a helping hand . “ Our goal is that every oncologist in every hospital in every corner of the human beings should adapt preciseness oncology , ” he asserted .
Join us at TechCrunch Sessions: AI
Exhibit at TechCrunch Sessions: AI
OneCell has develop a proprietary chalk bead that habituate antibodies and has an chemical attraction toward cancer cells . This helps filter circularize tumour cells from the affected role ’s blood sample .
The inauguration provides its biopsy testing for pan - cancer analysis for all solid tumors , including breast , lung , and colon cancers . However , it deliberately avoids first - metre Crab patients due to regulatory restrictions .
company in that domain are classified under FDA ’s breakthrough category , which requires premarket approvals . India does n’t have any such restrictions . nevertheless , since OneCell take aim to launch in the U.S. , it chose to place specifically the recurrence patient market .
“ Science and technology are passably knock-down and do work , but the business side of us have decided not to enter that very high - danger area , ” Uttarwar said .
The startup includes Guardant Health and Natera , as well as various Native American diagnostic company , among its competitors . However , Uttarwar recite TechCrunch the precision in diagnosis and affordability , which is one - twenty percent the price the competition charges , makes it stand apart .
found in 2021 , OneCell control under the B2B2C model , offer its biopsy testing to patient role through oncologists and hospital in India . It has an part in India ’s westerly city of Mumbai and a science laboratory in Pune , with a head count of 120 people . It also has 24 employees in the U.S. , let in those in its R&D quickness in Silicon Valley .
The startup design to start its business in the U.S. after over 2.5 years of serving India by working with biotech and biopharma society . It has developed the exam called OncoIndx Ikon to notice and analyze CTC , which will be usable in the U.S. through its local biomarker partners .
The early launch in India , one of thesignificant malignant neoplastic disease - affect countries , has help oneself OneCell gain enough data point to bolster its analytics and AI organisation and bring some of the top Amerindic hospitals on table , including state - run institute such as All India Institute of Medical Sciences , as well as secret hospitals Apollo , Fortis , and Tata Memorial Hospital . It also has strategic academic married person , including Harvard Medical School , Stanford University , and University of Georgia .
The tonic capital letter will aid OneCell blow up into the U.S. and surmount its business in India , Uttarwar say .
The startup projects to contact over 1,000 oncologists and a million patients in the near term .
